Opinion|Videos|December 19, 2025
Economic Burden and Systemwide Strategies
Panelists discuss how the economic toll of poor LDL-C control demands workplace and systemwide prevention strategies.
Advertisement
Episodes in this series
Panelists discuss how poor low-density lipoprotein cholesterol (LDL-C) control imposes substantial economic costs through hospitalizations, lost productivity, and long-term treatment of cardiovascular events.
They highlight that preventive strategies—such as workplace screenings and wellness incentives—can improve early detection and reduce downstream costs.
Panelists conclude that systemwide coordination between employers, payers, and clinicians is necessary to make cholesterol control a sustainable public health priority.
Advertisement
Related to this article
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy
2
Precision Drugs Meet Payer Realities
3
Cleveland Clinicians Say Obesity Care Starts Too Late for Many Patients
4
GOLD COPD Conference Turns to Earlier Diagnosis and Proactive Care
5